Stock Watch: Post-Pandemic Drug Commercialization Shifts
Sales Recovery Varied By Therapeutic Area And Class In 2022
Executive Summary
Emerging from the pandemic after nearly three years, therapy areas and drug classes are traveling at different speeds.
You may also be interested in...
Stock Watch: Reinforcements Required As Darzalex Carries J&J
Loss of exclusivity and other competitive pressures will continue to offset J&J’s pharmaceutical growth as its former blockbusters accumulate in ex-growth "other" categories. Can the pipeline take up the slack?
Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
Stock Watch: Why Novartis’s Q3 Misses Matter
Novartis’s use of the phrase “incident population” should have sent shock waves through companies developing gene and cellular therapies. Instead, like the stock price reaction to its lower revenues, the response was demure.